September 10, 2025Cancer Management and ResearchOpen Access

Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam

View Full Paper

Ask AI

Bookmark

Authors

HQHùng Nguyễn QuangVietnam Academy of Science and Technology PMPhuong Dao Manh MHMichael Hoa

Discussion

Member takes

Implication

This prospective analysis evaluates treatment response and factors influencing outcomes in HER2-positive breast cancer patients receiving neoadjuvant therapy.

Key Points

Neoadjuvant therapy leads to a favorable treatment response in 45% of HER2-positive breast cancer patients, highlighting its efficacy.
Young age and lower CA15-3 levels correlate with better treatment response in breast cancer patients, showing significant statistical associations.
This prospective, longitudinal study assesses the response to Docetaxel-Carboplatin-Trastuzumab after six treatment cycles, revealing positive outcomes.
These findings suggest that CA15-3 levels can help predict treatment efficacy, providing valuable insights for patient management in clinical settings.

Cite This Study

Quang et al. (2025) studied this question.

synapsesocial.com/papers/68c2443bb210217d647aa2f5 https://doi.org/10.2147/cmar.s537882

View Full Paper

Ask AI

Bookmark

Implication

This prospective analysis evaluates treatment response and factors influencing outcomes in HER2-positive breast cancer patients receiving neoadjuvant therapy.

Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam

Discussion

Member takes

Implication

Key Points

Cite This Study

Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider